The Filings Report

Royalty Pharma plc Class A Ordinary Shares

RPRXNasdaqCIK 1802768Healthcare / Drug Manufacturersfiscal year ends December29 quarters since 2019

Revenue, Q2 FY2026
$674M
+16.5% on Q2 FY2025
Net income
$18M
−44.4% on Q2 FY2025
Free cash flow
—
no year-earlier figure
Diluted EPS
$0.04
−42.9% on Q2 FY2025
Revenue, TTM
$2.5B
trailing four quarters
Net margin, TTM
32.1%
net income $815M
Free cash flow, TTM
—
Cash and equivalents
$812M
long-term debt $8.6B, Jun 30, 2026
Shares, 12-month change
—
— shares, Jun 30, 2026
Buybacks, TTM
$322M
no yield
Dividends, TTM
—
no yield
Market value
—
at the close, buybacks

Latest quarter Q2 FY2026, filed August 5, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Royalty Pharma plc Class A Ordinary Shares reported revenue of $674M, +16.5% on Q2 FY2025, and net income of $18M (−44.4%). Operating margin was 19.7%. Diluted earnings per share were $0.04.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 5, 2026.

Revenue and net incomeRevenueNet income
−$500M$0$500M$1.0BQ3'22, Revenue: $573MQ3'22, Net income: $143MQ3'22Q4'22, Revenue: $566MQ4'22, Net income: −$456MQ4'22Q1'23, Revenue: $684MQ1'23, Net income: $341MQ1'23Q2'23, Revenue: $538MQ2'23, Net income: $228MQ2'23Q3'23, Revenue: $536MQ3'23, Net income: $72MQ3'23Q4'23, Revenue: $596MQ4'23, Net income: $494MQ4'23Q1'24, Revenue: $568MQ1'24, Net income: $5MQ1'24Q2'24, Revenue: $537MQ2'24, Net income: $102MQ2'24Q3'24, Revenue: $565MQ3'24, Net income: $544MQ3'24Q4'24, Revenue: $594MQ4'24, Net income: $208MQ4'24Q1'25, Revenue: $568MQ1'25, Net income: $239MQ1'25Q2'25, Revenue: $579MQ2'25, Net income: $32MQ2'25Q3'25, Revenue: $609MQ3'25, Net income: $288MQ3'25Q4'25, Revenue: $622MQ4'25, Net income: $214MQ4'25Q1'26, Revenue: $631MQ1'26, Net income: $295MQ1'26Q2'26, Revenue: $674MQ2'26, Net income: $18MQ2'26−$500M$0$500M$1.0BQ3'22, Revenue: $573MQ3'22, Net income: $143MQ4'22, Revenue: $566MQ4'22, Net income: −$456MQ4'22Q1'23, Revenue: $684MQ1'23, Net income: $341MQ2'23, Revenue: $538MQ2'23, Net income: $228MQ2'23Q3'23, Revenue: $536MQ3'23, Net income: $72MQ4'23, Revenue: $596MQ4'23, Net income: $494MQ4'23Q1'24, Revenue: $568MQ1'24, Net income: $5MQ2'24, Revenue: $537MQ2'24, Net income: $102MQ2'24Q3'24, Revenue: $565MQ3'24, Net income: $544MQ4'24, Revenue: $594MQ4'24, Net income: $208MQ4'24Q1'25, Revenue: $568MQ1'25, Net income: $239MQ2'25, Revenue: $579MQ2'25, Net income: $32MQ2'25Q3'25, Revenue: $609MQ3'25, Net income: $288MQ4'25, Revenue: $622MQ4'25, Net income: $214MQ4'25Q1'26, Revenue: $631MQ1'26, Net income: $295MQ2'26, Revenue: $674MQ2'26, Net income: $18MQ2'26

Net income losses drawn in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$3B$5B$8B$10BQ3'22, Cash and equivalents: $992MQ3'22, Long-term debt: $6.1BQ3'22Q4'22, Cash and equivalents: $1.7BQ4'22, Long-term debt: $6.1BQ4'22Q1'23, Cash and equivalents: $2.0BQ1'23, Long-term debt: $6.1BQ1'23Q2'23, Cash and equivalents: $2.2BQ2'23, Long-term debt: $6.1BQ2'23Q3'23, Cash and equivalents: $936MQ3'23, Long-term debt: $6.1BQ3'23Q4'23, Cash and equivalents: $477MQ4'23, Long-term debt: $6.1BQ4'23Q1'24, Cash and equivalents: $843MQ1'24, Long-term debt: $6.1BQ1'24Q2'24, Cash and equivalents: $1.8BQ2'24, Long-term debt: $7.6BQ2'24Q3'24, Cash and equivalents: $950MQ3'24, Long-term debt: $6.6BQ3'24Q4'24, Cash and equivalents: $929MQ4'24, Long-term debt: $6.6BQ4'24Q1'25, Cash and equivalents: $1.1BQ1'25, Long-term debt: $6.6BQ1'25Q2'25, Cash and equivalents: $632MQ2'25, Long-term debt: $7.0BQ2'25Q3'25, Cash and equivalents: $939MQ3'25, Long-term debt: $8.6BQ3'25Q4'25, Cash and equivalents: $619MQ4'25, Long-term debt: $8.6BQ4'25Q1'26, Cash and equivalents: $586MQ1'26, Long-term debt: $8.6BQ1'26Q2'26, Cash and equivalents: $812MQ2'26, Long-term debt: $8.6BQ2'26$0$3B$5B$8B$10BQ3'22, Cash and equivalents: $992MQ3'22, Long-term debt: $6.1BQ4'22, Cash and equivalents: $1.7BQ4'22, Long-term debt: $6.1BQ4'22Q1'23, Cash and equivalents: $2.0BQ1'23, Long-term debt: $6.1BQ2'23, Cash and equivalents: $2.2BQ2'23, Long-term debt: $6.1BQ2'23Q3'23, Cash and equivalents: $936MQ3'23, Long-term debt: $6.1BQ4'23, Cash and equivalents: $477MQ4'23, Long-term debt: $6.1BQ4'23Q1'24, Cash and equivalents: $843MQ1'24, Long-term debt: $6.1BQ2'24, Cash and equivalents: $1.8BQ2'24, Long-term debt: $7.6BQ2'24Q3'24, Cash and equivalents: $950MQ3'24, Long-term debt: $6.6BQ4'24, Cash and equivalents: $929MQ4'24, Long-term debt: $6.6BQ4'24Q1'25, Cash and equivalents: $1.1BQ1'25, Long-term debt: $6.6BQ2'25, Cash and equivalents: $632MQ2'25, Long-term debt: $7.0BQ2'25Q3'25, Cash and equivalents: $939MQ3'25, Long-term debt: $8.6BQ4'25, Cash and equivalents: $619MQ4'25, Long-term debt: $8.6BQ4'25Q1'26, Cash and equivalents: $586MQ1'26, Long-term debt: $8.6BQ2'26, Cash and equivalents: $812MQ2'26, Long-term debt: $8.6BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Royalty Pharma plc Class A Ordinary Shares income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 8, 2025Q4 FY2024ended Dec 31, 2024filed Feb 12, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue674631622609579568594565+16.5%
Cost of revenue—————————
Gross profit—————————
Research and development984051513015111−67.4%
Selling, general and administrative1621591641191801116857−9.9%
Operating income133563388427210534362735−36.5%
Other income (expense)(52)(95)(32)17(117)(100)(27)71+55.9%
Pretax income8146835644493434334806−12.0%
Income tax00000000—
Net income1829521428832239208544−44.4%
Diluted EPS ($)0.040.67—0.670.070.55—1.21−42.9%
Diluted shares (millions)557557—560562578—593—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Royalty Pharma plc Class A Ordinary Shares balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 8, 2025Q4 FY2024ended Dec 31, 2024filed Feb 12, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents8125866199396321,088929950+28.5%
Short-term investments2522191613125849+89.4%
Total current assets1,7651,4261,5281,8501,5201,8431,8021,794+16.1%
Total assets19,82019,81519,62119,34718,32317,60818,22318,042+8.2%
Total current liabilities6315366365311,2071,1831,2541,168−47.7%
Long-term debt8,5828,5768,5718,5667,0036,6196,6156,610+22.5%
Total liabilities10,0349,8799,9069,7268,8207,8207,8807,784+13.8%
Stockholders’ equity—————————
Shares outstanding (millions)—————————

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Royalty Pharma plc Class A Ordinary Shares cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 8, 2025Q4 FY2024ended Dec 31, 2024filed Feb 12, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow728718827703364596743704+100.1%
Capital expenditures—————————
Free cash flow (CFO − capex)—————————
Depreciation and amortization—————————
Share repurchases4550811462927095397−84.7%
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 11, 2026.

Income statement

Royalty Pharma plc Class A Ordinary Shares income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 11, 2026FY2024ended Dec 31, 2024filed Feb 12, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 15, 2023FY2021ended Dec 31, 2021filed Feb 15, 2022FY2020ended Dec 31, 2020filed Feb 24, 2021FY2019ended Dec 31, 2019filed Aug 12, 2020FY2018ended Dec 31, 2018filed Feb 24, 2021
Revenue2,3782,2642,3552,2372,2892,1221,8141,795
Cost of revenue————————
Gross profit————————
Research and development4522521772002683393
Selling, general and administrative57323725022718318210362
Operating income1,5601,2921,4923071,4311,5952,6231,364
Other income (expense)(235)38208(77)(190)107(162)153
Pretax income1,3241,3311,7002301,2411,7022,4611,518
Income tax00000000
Net income7718591,135436209752,3491,378
Diluted EPS ($)1.781.912.530.101.491.32——
Diluted shares (millions)564594603438415375——

Balance sheet

Royalty Pharma plc Class A Ordinary Shares balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 11, 2026FY2024ended Dec 31, 2024filed Feb 12, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 15, 2023FY2021ended Dec 31, 2021filed Feb 15, 2022FY2020ended Dec 31, 2020filed Feb 24, 2021FY2019ended Dec 31, 2019filed Aug 12, 2020FY2018ended Dec 31, 2018filed Feb 24, 2021
Cash and equivalents6199294771,7111,5411,009246—
Short-term investments195818166700—
Total current assets1,5281,8021,2742,5552,8782,697832—
Total assets19,62118,22316,38216,81317,51616,02012,450—
Total current liabilities6361,2541611,167171308333—
Long-term debt8,5716,6156,1356,1197,0965,8175,956—
Total liabilities9,9067,8806,2987,2887,2676,1246,308—
Stockholders’ equity————————
Shares outstanding (millions)————————

Cash flow statement

Royalty Pharma plc Class A Ordinary Shares cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 11, 2026FY2024ended Dec 31, 2024filed Feb 12, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 15, 2023FY2021ended Dec 31, 2021filed Feb 15, 2022FY2020ended Dec 31, 2020filed Feb 24, 2021FY2019ended Dec 31, 2019filed Aug 12, 2020FY2018ended Dec 31, 2018filed Feb 24, 2021
Operating cash flow2,4902,7692,9882,1442,0182,0351,6671,618
Capital expenditures————————
Free cash flow (CFO − capex)————————
Depreciation and amortization————————
Share repurchases1,22723030500040
Dividends paid————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$13M
7 sales by 3 insiders; officers and directors $13M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$93M
74 sales by 5 insiders; officers and directors $93M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 5, 2026Urist MarshallEVP, Research & Investmentsopen-market sale10b5-14,126$57.10$236K0Oct 5, 2026
Sep 30, 2026Bassler Bonnie LDirectoraward642$58.41$37K79,823Sep 30, 2026
Sep 28, 2026Urist MarshallEVP, Research & Investmentsopen-market sale10b5-14,126$57.88$239K4,126Sep 30, 2026
Sep 22, 2026Hite ChristopherEVP & Chairman, Partneringopen-market sale10b5-1indirect96,073$58.51$6M274,328Sep 24, 2026
Sep 22, 2026Hite ChristopherEVP & Chairman, Partneringopen-market sale10b5-1indirect3,927$58.93$231K270,401Sep 24, 2026
Aug 19, 2026Hite ChristopherEVP & Chairman, Partneringgift16,800$0.00—23,200Aug 19, 2026
Aug 18, 2026Hite ChristopherEVP & Chairman, Partneringopen-market sale10b5-1indirect100,000$59.97$6M370,401Aug 19, 2026
Aug 13, 2026Coyne Terrance P.EVP & CFOopen-market sale10b5-1indirect9,230$58.59$541K1,772Aug 17, 2026
Aug 13, 2026Coyne Terrance P.EVP & CFOopen-market sale10b5-1indirect1,772$59.14$105K0Aug 17, 2026
Aug 5, 2026Legorreta Pablo G.CEO, Chairman of the Board, Directoraward65,216$0.00—1MAug 7, 2026
Aug 5, 2026Coyne Terrance P.EVP & CFOawardindirect11,002$0.00—11,002Aug 7, 2026
Aug 5, 2026Hite ChristopherEVP & Chairman, Partneringawardindirect11,002$0.00—470,401Aug 7, 2026
Aug 5, 2026Urist MarshallEVP, Research & Investmentsaward8,252$0.00—8,252Aug 7, 2026
Jul 1, 2026Urist MarshallEVP, Research & Investmentsopen-market sale10b5-19,099$55.88$508K0Jul 2, 2026
Jun 30, 2026Hite ChristopherEVP & Chairman, Partneringopen-market sale10b5-1indirect97,446$56.50$6M461,953Jul 2, 2026
Jun 30, 2026Hite ChristopherEVP & Chairman, Partneringopen-market sale10b5-1indirect2,554$57.10$146K459,399Jul 2, 2026
Jun 30, 2026Hite ChristopherEVP & Chairman, Partneringopen-market sale10b5-129,400$56.44$2M40,600Jul 2, 2026
Jun 30, 2026Hite ChristopherEVP & Chairman, Partneringopen-market sale10b5-1600$57.09$34K40,000Jul 2, 2026
Jun 30, 2026Bassler Bonnie LDirectoraward689$54.40$37K79,181Jun 30, 2026
Jun 24, 2026Urist MarshallEVP, Research & Investmentsopen-market sale10b5-19,098$55.18$502K9,099Jun 25, 2026
Jun 23, 2026Hite ChristopherEVP & Chairman, Partneringopen-market sale10b5-1indirect32,408$54.11$2M676,991Jun 25, 2026
Jun 23, 2026Hite ChristopherEVP & Chairman, Partneringopen-market sale10b5-1indirect117,592$54.47$6M559,399Jun 25, 2026
Jun 5, 2026Weatherman Elizabeth HDirectoraward4,545$0.00—13,103Jun 8, 2026
Jun 5, 2026Norden GregoryDirectoraward4,545$0.00—196,348Jun 8, 2026
Jun 5, 2026Love Ted WDirectoraward4,545$0.00—58,393Jun 8, 2026

Full insider history for Royalty Pharma plc Class A Ordinary Shares, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Royalty Pharma plc, CIK 1802768 on EDGAR
Extract generated
November 1, 2026
Withheld
none
Repaired
3 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: net income FY2022, operating income FY2022, pretax income FY2022
XBRL concepts behind each line

Income statement

Revenue: Revenues
Cost of revenue: not filed
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: not filed
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: not filed
Free cash flow (CFO − capex): not filed
Depreciation and amortization: not filed
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 1, 2026.

JSON file
/data/financials/RPRX.json